House
GuidelinesCalculatorsPricingBlog
Ask House ↗
Guidelines↗Calculators↗Pricing↗Blog↗
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
Back to guidelines
Urology

Non-neurogenic male lower urinary tract symptoms

EAU · 2026 edition / updateSource checked 29 October 2026
Read the source publication
House clinical summary

Scope

The EAU male LUTS guideline treats urinary symptoms as potentially multifactorial rather than assuming every presentation is prostate obstruction. This selected pathway covers assessment, conservative and medicine choices, common surgical indications, nocturnal polyuria and follow-up in non-neurogenic, nonmalignant disease.

Written by House with AI assistance · AI-assisted source check 29 October 2026.

This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.

Establish the cause and degree of bother

  • Take a complete medical and surgical history, including medicines and relevant comorbidities, and assess symptoms, bother and quality of life with a validated questionnaire. Examine the patient including digital rectal examination, and perform urinalysis; abnormal findings need appropriate further investigation. [1]
  • Use a bladder diary for at least three days, particularly for nocturia. Document voided volumes and timing so storage symptoms and excessive night-time urine production can be distinguished. [1]
  • Measure post-void residual and perform uroflowmetry before medical or invasive treatment. A large residual or poor flow alone does not establish obstruction: poor detrusor contraction or an underfilled bladder may produce similar findings. [1]
  • Offer PSA testing when cancer diagnosis would change management or the result would help treatment decisions, after discussing implications. Assess renal function if impairment is suspected, hydronephrosis is present or surgery is being considered. [1]
  • Image prostate size when planning surgery; consider imaging when it helps medicine choice. Consider cystoscopy when it could change diagnosis or treatment. Reserve urodynamics for selected indications or unclear mechanisms rather than routinely testing every surgical candidate. [1]

Match medicine treatment to symptoms and progression risk

  • Offer watchful waiting for minimally bothersome mild or moderate symptoms. Provide lifestyle and self-care advice before or alongside treatment, including tailored fluid timing, moderating caffeine or alcohol, reviewing medicines, relaxed or double voiding and constipation management. [1]
  • Alpha blockers are recommended for moderate to severe LUTS and have a relatively rapid effect, but do not prevent long-term retention or need for surgery. Discuss dizziness, orthostatic hypotension and ejaculatory changes, and notify the ophthalmologist before cataract surgery. [1]
  • Use a 5-alpha-reductase inhibitor for moderate to severe symptoms with increased progression risk, for example prostate volume above 40 mL. Explain the slow onset, long-term treatment and sexual adverse effects; these agents can reduce future retention and surgery. [1]
  • For moderate to severe LUTS with increased progression risk, such as a prostate above 40 mL, offer an alpha blocker plus a 5-alpha-reductase inhibitor. This combined strategy is aimed at both symptom relief and progression risk. [1]
  • For moderate-to-severe LUTS with predominantly storage symptoms, antimuscarinic medicines are an option, with repeat symptom and residual-volume checks. The guideline advises against use when post-void residual exceeds 150 mL; stop and reassess if voiding symptoms or stream worsen. [1]
  • Beta-3 agonists are recommended for moderate to severe storage symptoms. For mirabegron, measure blood pressure before treatment and regularly thereafter; it is contraindicated at uncontrolled systolic pressure at least 180 mmHg or diastolic pressure at least 110 mmHg. [1]
  • PDE5 inhibitors are a treatment option for moderate to severe LUTS with or without erectile dysfunction. Tadalafil 5 mg once daily is the licensed LUTS regimen described here; do not use with nitrates or guanylate-cyclase stimulators, or when cardiac disease makes sexual activity inadvisable. Check the full cardiovascular and eye contraindications before prescribing. [1]
  • For moderate-to-severe LUTS, if storage symptoms persist despite an alpha blocker or antimuscarinic alone, the combination may be considered, but not when residual exceeds 150 mL. An alpha blocker plus beta-3 agonist is another conditional option after persistent storage symptoms on alpha-blocker monotherapy. [1]

Recognize when procedures are needed

  • Surgery is usually required for recurrent or refractory retention, overflow incontinence, recurrent urinary infection, bladder stones or diverticula, treatment-resistant visible bleeding from benign prostatic enlargement, or upper-tract dilatation from obstruction with or without renal impairment. [1]
  • Inadequate relief despite conservative or medical treatment is also a reason to consider surgery. Select a procedure using prostate anatomy and size, comorbidities, anaesthetic suitability, patient preferences about adverse effects and local surgical expertise. [1]
  • For moderate to severe LUTS requiring surgery, TURP is recommended for prostate size 30–80 mL. Transurethral incision is recommended below 30 mL when there is no middle lobe. HoLEP is a recommended alternative to TURP or open surgery for LUTS caused by benign prostatic obstruction. [1]
  • Aquablation is an alternative for moderate to severe LUTS/BPO with prostate volume 30–80 mL, particularly when preserving ejaculation matters. Prostatic urethral lift is recommended for men prioritizing ejaculation with prostates below 70 mL and no middle lobe; explain its higher retreatment rate than TURP. [1]

Address nocturia, incontinence and poor emptying

  • Investigate nocturia for behavioural, systemic and sleep causes as well as urinary dysfunction; obstructive sleep apnoea is an example. Discuss behavioural changes to reduce night-time urine production and improve sleep. [1]
  • Desmopressin may be offered for nocturnal-polyuria-related nocturia in men under 65 after assessing underlying causes. Discuss hyponatraemia and individual benefit versus harm, particularly in older men; avoid fluids from at least one hour before until eight hours after dosing. [1]
  • With desmopressin, check sodium at baseline, day three, day seven, one month and periodically; monitor more often in older people and those at greater hyponatraemia risk. Restart the monitoring sequence after dose escalation. Do not initiate low-dose treatment in older men with below-normal sodium. [1]
  • For male incontinence, assess type, comorbidities, medicines, diary and residual. Offer bladder training and appropriate conservative care; urgency incontinence persisting despite conservative treatment can be treated with antimuscarinic or beta-3 therapy. Stress incontinence follows a different pathway. [1]
  • For underactive bladder, consider intermittent catheterization when upper-tract damage is a risk or residual exceeds 300 mL. Do not routinely use parasympathomimetics; an indwelling urethral or suprapubic catheter is reserved for situations where other drainage options fail or are unsuitable. [1]

Review response and adverse effects

  • Review watchful waiting at six months and then annually if stable. Most alpha-blocker, antimuscarinic, beta-3 or PDE5 treatment needs an initial review after four to six weeks, followed by six-month and annual review if effective and tolerated; reassess earlier with deterioration. [1]
  • Review 5-alpha-reductase inhibitors at 12 weeks and six months. Establish a new PSA baseline at six months and evaluate a confirmed rise on treatment; regular PSA monitoring applies when life expectancy exceeds ten years and cancer diagnosis could change management. After prostate surgery, review response and adverse effects four to six weeks after catheter removal. [1]

Limitations and use

  • Selected formal recommendations and practical contexts were consulted. This is not the complete procedural comparison, medicine contraindication list, male-incontinence surgery pathway, young-men bladder-neck/dysfunctional-voiding pathway or evaluation of neurogenic and malignant disease. Prostate-size cutoffs refer to particular procedures rather than a universal rule for surgery. Follow-up schedules in this guideline rely largely on empirical or theoretical practice rather than comparative trials.

This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.

Summary sources

  1. 1
    Non-neurogenic male lower urinary tract symptoms

    Selected recommendation material consulted

Clinical guideline

Publication details

Issuing organisation
EAU
Resource type
Clinical guideline · House clinical summary
Source setting
Europe

Earlier House summaries: benign prostatic hyperplasia eau

The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.

On this page

  • Scope
  • Establish the cause and degree of bother
  • Match medicine treatment to symptoms and progression risk
  • Recognize when procedures are needed
  • Address nocturia, incontinence and poor emptying
  • Review response and adverse effects
  • Limitations and use
  • Summary sources
  • Publication details
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House